SlideShare uma empresa Scribd logo
1 de 81
Hypertension Physiology, Pathophysiology and Clinical Managements Jun  Tao
Stroke and Ischemic Heart Disease (IHD) Mortality Rate in Each Decade of Age, Versus Usual Systolic BP at the Start of that Decade Mortality* Usual SBP (mmHg) 50–59 y 60–69 y 70–79 y 80–89 y Stroke Age at risk 256 128 64 32 16 8 4 2 1 0 120 140 160 180 IHD Usual SBP (mmHg ) 50–59 y 60–69 y 70–79 y 80–89 y Age at risk 40–49 y 256 128 64 32 16 8 4 2 1 0 120 140 160 180 *Floating absolute risk and 95% CI Reproduced from The Lancet, 360, Lewington et al. pp. 1903–13 Copyright  © 2002, with permission from Elsevier
Introduction ,[object Object]
[object Object]
[object Object]
Primary hypertension
Etiology and pathogenesis ,[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object]
[object Object],[object Object]
[object Object],[object Object],[object Object]
[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Pathology ,[object Object]
Blood vessel change ,[object Object],[object Object]
[object Object]
 
[object Object]
[object Object],[object Object]
[object Object],[object Object]
[object Object]
Specific organ changes in hypertension ,[object Object],[object Object]
[object Object]
Hpertrophy of left ventricle
 
[object Object],[object Object]
[object Object]
 
 
[object Object],[object Object]
[object Object]
肾动脉硬化 肾动脉硬化 致密的肾盂 X 线影象
Malignant hypertension:  Fibrinoid necrosis of damaged arteriole of kidney
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
 
Symptoms ,[object Object],[object Object]
[object Object]
[object Object],[object Object]
[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object]
Symptoms associated with target organ damage ,[object Object],[object Object]
[object Object],[object Object]
[object Object],[object Object]
[object Object],[object Object]
Complications  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
physical examination  ,[object Object],[object Object],[object Object]
Diagnosis  ,[object Object]
 
CVD Risk Factors ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],*Components of the metabolic syndrome.
Cardiovascular risk category of hypertension   Blood pressure ( mmHg )   Grade 1(SBP 140 ~ 159 or DBP 90 ~ 99)  Grade 2(SBP 160 ~ 179 or DBP 100 ~ 109) Grade 3(SBP ≥180 or DBP ≥110) No other risk factors Low-risk   Medium-risk High-risk   1 ~ 2  risk factors Moderate-risk   Medium-risk Very High-risk 3 or more  risk factors   , or diabetes , or target organ damage High-risk   High-risk   Very High-risk complications Very High-risk Very High-risk Very High-risk
Laboratory examinations ,[object Object],[object Object],[object Object]
Goals of Therapy ,[object Object],[object Object],[object Object]
Blood Pressure Reduction of 2 mmHg Decreases the Risk of Cardiovascular Events by 7–10% ,[object Object],[object Object],[object Object],2 mmHg decrease in mean SBP 10% reduction in risk of stroke mortality 7% reduction in risk of ischaemic heart disease mortality Lewington et al. Lancet 2002;360:1903–13
Lifestyle Modification ,[object Object],[object Object]
[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
Algorithm for Treatment of Hypertension Not at Goal Blood Pressure (<140/90 mmHg)  (<130/80 mmHg for those with diabetes or chronic kidney disease) Initial Drug Choices Lifestyle Modifications Drug(s) for the compelling indications  Other antihypertensive drugs (diuretics, ACEI, ARB, BB, CCB)  as needed.  With Compelling  Indications Stage 2 Hypertension   (SBP  > 160 or DBP  > 100 mmHg)  2-drug combination for most (usually thiazide-type diuretic and  ACEI, or ARB, or BB, or CCB) Stage 1 Hypertension (SBP 140–159 or DBP 90–99 mmHg)  Thiazide-type diuretics for most.  May consider ACEI, ARB, BB, CCB,  or combination. Without Compelling  Indications Not at Goal  Blood Pressure Optimize dosages or add additional drugs  until goal blood pressure is achieved. Consider consultation with hypertension specialist.
Drug treatment  ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],,
 
 
Classification and Management  of BP for adults *Treatment determined by highest BP category. † Initial combined therapy should be used cautiously in those at risk for orthostatic hypotension. ‡ Treat patients with chronic kidney disease or diabetes to BP goal of <130/80 mmHg.  BP classification   SBP* mmHg   DBP* mmHg  Lifestyle modification   Initial drug therapy   Without compelling indication  With compelling indications Normal  <120  and <80  Encourage  Prehypertension  120–139  or 80–89  Yes  No antihypertensive drug indicated.  Drug(s) for compelling indications.  ‡   Stage 1 Hypertension  140–159  or 90–99  Yes  Thiazide-type diuretics for most.  May consider ACEI, ARB, BB, CCB, or combination.  Drug(s) for the compelling indications. ‡ Other antihypertensive drugs (diuretics, ACEI, ARB, BB, CCB) as needed.  Stage 2 Hypertension  > 160  or  > 100  Yes  Two-drug combination for most †  (usually thiazide-type diuretic and ACEI or ARB or BB or CCB).
 
 
Other medications for hypertensive patients Primary prevention ( 1 ) Aspirin: use 75mg daily if patient is aged   50 years with blood pressure controlled to <150/90 mm Hg and either; target organ damage, diabetes mellitus, or 10 year risk of cardiovascular disease of   20% (measured by using the new Joint British Societies’ cardiovascular disease risk chart) ( 2 ) Statin: use sufficient doses to reach targets if patient is aged up to at least 80 years, with a 10 year risk of cardiovascular disease of   20% (measured by using the new Joint British Societies’ cardiovascular disease risk chart) and with total cholesterol concentration   3.5mmol/l ( 3 ) Vitamins—no benefit shown, do not prescribe
[object Object],[object Object],[object Object],[object Object],[object Object],Other medications for hypertensive patients
Targets for lipid lowering Ideal - TC<4.0mmol/l or LDL <2.0mmol/l or 25%    in TC or 30%    in LDL-C whichever is the greater ‘ Audit’ - TC <5.0mmol/l or LDL <3.0mmol/l or 25%    in TC or 30%    in LDL-C whichever is the greater Lipid targets
[object Object]
CVD Risk Factors ,[object Object],[object Object],[object Object]
Target organ damage ,[object Object],[object Object],[object Object],[object Object],[object Object]
ESH - ESC Guidelines, J Hypertens 2008 -BP < 140/90 mmHg in all hypertensive patients < 130/80 mmHg in hypertensive patients  with diabetes or renal disease -Control of all cardiovascular risk factors Goals of treatment
About drug treatment ,[object Object],[object Object],[object Object]
Screening and treatment of secondary forms of hypertension ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
谢谢!

Mais conteúdo relacionado

Mais procurados (20)

Hypertention ppt
Hypertention pptHypertention ppt
Hypertention ppt
 
Arrhythmias
ArrhythmiasArrhythmias
Arrhythmias
 
Atrial fibrillation
Atrial  fibrillation Atrial  fibrillation
Atrial fibrillation
 
HF update 2021
HF update 2021HF update 2021
HF update 2021
 
Hypertension
HypertensionHypertension
Hypertension
 
SGLT2 inhibitors in Heart failure: A prized addition to HF treatment options
SGLT2 inhibitors in Heart failure: A prized addition to HF treatment optionsSGLT2 inhibitors in Heart failure: A prized addition to HF treatment options
SGLT2 inhibitors in Heart failure: A prized addition to HF treatment options
 
Diabetic nephropathy
Diabetic nephropathyDiabetic nephropathy
Diabetic nephropathy
 
Hypertension
HypertensionHypertension
Hypertension
 
Management of Hypertension
 Management of Hypertension Management of Hypertension
Management of Hypertension
 
Diabetes mellitus and hypertension
Diabetes mellitus and hypertensionDiabetes mellitus and hypertension
Diabetes mellitus and hypertension
 
Supraventricular tacchycardias
Supraventricular tacchycardias Supraventricular tacchycardias
Supraventricular tacchycardias
 
Ventricular tachycardia
Ventricular tachycardiaVentricular tachycardia
Ventricular tachycardia
 
cardiovascular remodeling and it's prevention
cardiovascular remodeling and it's preventioncardiovascular remodeling and it's prevention
cardiovascular remodeling and it's prevention
 
Hypertension (HTN)
Hypertension (HTN)Hypertension (HTN)
Hypertension (HTN)
 
Acute Coronary Syndrome
Acute Coronary SyndromeAcute Coronary Syndrome
Acute Coronary Syndrome
 
Heart failure ppt
Heart failure ppt Heart failure ppt
Heart failure ppt
 
Diabetic cardiomyopathy
Diabetic cardiomyopathyDiabetic cardiomyopathy
Diabetic cardiomyopathy
 
Essential Hypertension
Essential HypertensionEssential Hypertension
Essential Hypertension
 
Novel approaches in Lipid Management
Novel approaches in Lipid ManagementNovel approaches in Lipid Management
Novel approaches in Lipid Management
 
Pcsk 9 inhibitors
Pcsk 9 inhibitorsPcsk 9 inhibitors
Pcsk 9 inhibitors
 

Destaque

Cardiomyopathy
CardiomyopathyCardiomyopathy
Cardiomyopathyfitango
 
Cardiac hyprtrophy and heart failure
Cardiac hyprtrophy and heart failureCardiac hyprtrophy and heart failure
Cardiac hyprtrophy and heart failureayeayetun08
 
Ischemic Heart Disease.ppt
Ischemic Heart Disease.pptIschemic Heart Disease.ppt
Ischemic Heart Disease.pptShama
 
Pulmonary hypertension (2014) dr.tinku joseph
Pulmonary hypertension (2014) dr.tinku josephPulmonary hypertension (2014) dr.tinku joseph
Pulmonary hypertension (2014) dr.tinku josephDr.Tinku Joseph
 
Cardiovascular Disease.ppt
Cardiovascular Disease.pptCardiovascular Disease.ppt
Cardiovascular Disease.pptShama
 
Coronary heart diseases ppt
Coronary heart diseases pptCoronary heart diseases ppt
Coronary heart diseases pptUma Binoy
 
VALVULAR HEART DISEASE
VALVULAR HEART DISEASEVALVULAR HEART DISEASE
VALVULAR HEART DISEASEhanisahwarrior
 

Destaque (12)

Cardiomyopathy
CardiomyopathyCardiomyopathy
Cardiomyopathy
 
Cardiac hyprtrophy and heart failure
Cardiac hyprtrophy and heart failureCardiac hyprtrophy and heart failure
Cardiac hyprtrophy and heart failure
 
Cardiomyopathies
CardiomyopathiesCardiomyopathies
Cardiomyopathies
 
Ischemic Heart Disease
Ischemic Heart DiseaseIschemic Heart Disease
Ischemic Heart Disease
 
Ischemic Heart Disease.ppt
Ischemic Heart Disease.pptIschemic Heart Disease.ppt
Ischemic Heart Disease.ppt
 
Pulmonary hypertension (2014) dr.tinku joseph
Pulmonary hypertension (2014) dr.tinku josephPulmonary hypertension (2014) dr.tinku joseph
Pulmonary hypertension (2014) dr.tinku joseph
 
Cardiovascular Disease.ppt
Cardiovascular Disease.pptCardiovascular Disease.ppt
Cardiovascular Disease.ppt
 
Heart Disease
Heart DiseaseHeart Disease
Heart Disease
 
Valvular heart disease and anaesthesia
Valvular heart disease and anaesthesiaValvular heart disease and anaesthesia
Valvular heart disease and anaesthesia
 
Coronary heart diseases ppt
Coronary heart diseases pptCoronary heart diseases ppt
Coronary heart diseases ppt
 
Heart disease
Heart disease Heart disease
Heart disease
 
VALVULAR HEART DISEASE
VALVULAR HEART DISEASEVALVULAR HEART DISEASE
VALVULAR HEART DISEASE
 

Semelhante a 10 hypertension (20)

HYPERTENSION
HYPERTENSIONHYPERTENSION
HYPERTENSION
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
1. Hypertension (2).pptx
1. Hypertension (2).pptx1. Hypertension (2).pptx
1. Hypertension (2).pptx
 
Hypertension
HypertensionHypertension
Hypertension
 
L5 &amp; 6 effects of htn on vessels &amp; heart 20 (2)
L5 &amp; 6 effects of htn on vessels &amp; heart 20 (2)L5 &amp; 6 effects of htn on vessels &amp; heart 20 (2)
L5 &amp; 6 effects of htn on vessels &amp; heart 20 (2)
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension (htn)
Hypertension (htn)Hypertension (htn)
Hypertension (htn)
 
hypertension.pptx
hypertension.pptxhypertension.pptx
hypertension.pptx
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension - Approach & Management
Hypertension - Approach & ManagementHypertension - Approach & Management
Hypertension - Approach & Management
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 
Lecture 8 hypertension - Pathology
Lecture 8 hypertension - Pathology Lecture 8 hypertension - Pathology
Lecture 8 hypertension - Pathology
 
PATHOLOGY OF HYPERTENSION .ppt
PATHOLOGY OF HYPERTENSION           .pptPATHOLOGY OF HYPERTENSION           .ppt
PATHOLOGY OF HYPERTENSION .ppt
 
Essential hypertension management and treatment
Essential hypertension management  and treatmentEssential hypertension management  and treatment
Essential hypertension management and treatment
 
HYPERTENSION (4).ppt
HYPERTENSION (4).pptHYPERTENSION (4).ppt
HYPERTENSION (4).ppt
 
Hypertension
HypertensionHypertension
Hypertension
 
Hypertension
HypertensionHypertension
Hypertension
 

Mais de internalmed

内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文internalmed
 
C:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitusC:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitusinternalmed
 
C:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
C:\documents and settings\administrator\桌面\20100607 nephrotic syndromeC:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
C:\documents and settings\administrator\桌面\20100607 nephrotic syndromeinternalmed
 
C:\Documents And Settings\Administrator\桌面\内分泌总论英文
C:\Documents And Settings\Administrator\桌面\内分泌总论英文C:\Documents And Settings\Administrator\桌面\内分泌总论英文
C:\Documents And Settings\Administrator\桌面\内分泌总论英文internalmed
 
内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文internalmed
 
内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文internalmed
 
Foreign students acute leukemia-zhou
Foreign students acute leukemia-zhouForeign students acute leukemia-zhou
Foreign students acute leukemia-zhouinternalmed
 
24 glomerular disease
24 glomerular disease24 glomerular disease
24 glomerular diseaseinternalmed
 
23 renal disease
23 renal disease23 renal disease
23 renal diseaseinternalmed
 
22 acute pancreatitis
22 acute pancreatitis22 acute pancreatitis
22 acute pancreatitisinternalmed
 
21 ulcerative colitis
21 ulcerative colitis21 ulcerative colitis
21 ulcerative colitisinternalmed
 
20 hepatic enchephalopathy
20 hepatic enchephalopathy20 hepatic enchephalopathy
20 hepatic enchephalopathyinternalmed
 
19 hepatic cirrhosis
19 hepatic cirrhosis19 hepatic cirrhosis
19 hepatic cirrhosisinternalmed
 
17 pericardial disease
17 pericardial disease17 pericardial disease
17 pericardial diseaseinternalmed
 
17 chronic gastritis gao
17 chronic gastritis gao17 chronic gastritis gao
17 chronic gastritis gaointernalmed
 
16 arrhythmias2009
16 arrhythmias200916 arrhythmias2009
16 arrhythmias2009internalmed
 
再障 2010.5.13
再障 2010.5.13再障 2010.5.13
再障 2010.5.13internalmed
 
Chronic renal failure(2010505)
Chronic renal failure(2010505)Chronic renal failure(2010505)
Chronic renal failure(2010505)internalmed
 

Mais de internalmed (20)

内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文
 
C:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitusC:\documents and settings\administrator\桌面\35 ndiabetes mellitus
C:\documents and settings\administrator\桌面\35 ndiabetes mellitus
 
C:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
C:\documents and settings\administrator\桌面\20100607 nephrotic syndromeC:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
C:\documents and settings\administrator\桌面\20100607 nephrotic syndrome
 
C:\Documents And Settings\Administrator\桌面\内分泌总论英文
C:\Documents And Settings\Administrator\桌面\内分泌总论英文C:\Documents And Settings\Administrator\桌面\内分泌总论英文
C:\Documents And Settings\Administrator\桌面\内分泌总论英文
 
内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文
 
内分泌总论英文
内分泌总论英文内分泌总论英文
内分泌总论英文
 
Foreign students acute leukemia-zhou
Foreign students acute leukemia-zhouForeign students acute leukemia-zhou
Foreign students acute leukemia-zhou
 
24 glomerular disease
24 glomerular disease24 glomerular disease
24 glomerular disease
 
23 renal disease
23 renal disease23 renal disease
23 renal disease
 
22 acute pancreatitis
22 acute pancreatitis22 acute pancreatitis
22 acute pancreatitis
 
21 ulcerative colitis
21 ulcerative colitis21 ulcerative colitis
21 ulcerative colitis
 
20 hepatic enchephalopathy
20 hepatic enchephalopathy20 hepatic enchephalopathy
20 hepatic enchephalopathy
 
19 hepatic cirrhosis
19 hepatic cirrhosis19 hepatic cirrhosis
19 hepatic cirrhosis
 
18 peptic ulcer
18 peptic ulcer18 peptic ulcer
18 peptic ulcer
 
17 pericardial disease
17 pericardial disease17 pericardial disease
17 pericardial disease
 
17 chronic gastritis gao
17 chronic gastritis gao17 chronic gastritis gao
17 chronic gastritis gao
 
16 arrhythmias2009
16 arrhythmias200916 arrhythmias2009
16 arrhythmias2009
 
再障 2010.5.13
再障 2010.5.13再障 2010.5.13
再障 2010.5.13
 
Gastric cancer
Gastric cancerGastric cancer
Gastric cancer
 
Chronic renal failure(2010505)
Chronic renal failure(2010505)Chronic renal failure(2010505)
Chronic renal failure(2010505)
 

Último

Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3JemimahLaneBuaron
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdfQucHHunhnh
 
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhikauryashika82
 
Measures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SDMeasures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SDThiyagu K
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfagholdier
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxiammrhaywood
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactdawncurless
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104misteraugie
 
fourth grading exam for kindergarten in writing
fourth grading exam for kindergarten in writingfourth grading exam for kindergarten in writing
fourth grading exam for kindergarten in writingTeacherCyreneCayanan
 
Student login on Anyboli platform.helpin
Student login on Anyboli platform.helpinStudent login on Anyboli platform.helpin
Student login on Anyboli platform.helpinRaunakKeshri1
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxheathfieldcps1
 
Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..Disha Kariya
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeThiyagu K
 
A Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformA Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformChameera Dedduwage
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introductionMaksud Ahmed
 
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdfSoniaTolstoy
 
General AI for Medical Educators April 2024
General AI for Medical Educators April 2024General AI for Medical Educators April 2024
General AI for Medical Educators April 2024Janet Corral
 
Arihant handbook biology for class 11 .pdf
Arihant handbook biology for class 11 .pdfArihant handbook biology for class 11 .pdf
Arihant handbook biology for class 11 .pdfchloefrazer622
 

Último (20)

Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3Q4-W6-Restating Informational Text Grade 3
Q4-W6-Restating Informational Text Grade 3
 
Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1
 
1029-Danh muc Sach Giao Khoa khoi 6.pdf
1029-Danh muc Sach Giao Khoa khoi  6.pdf1029-Danh muc Sach Giao Khoa khoi  6.pdf
1029-Danh muc Sach Giao Khoa khoi 6.pdf
 
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in DelhiRussian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
Russian Escort Service in Delhi 11k Hotel Foreigner Russian Call Girls in Delhi
 
Measures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SDMeasures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SD
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impact
 
Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104Nutritional Needs Presentation - HLTH 104
Nutritional Needs Presentation - HLTH 104
 
fourth grading exam for kindergarten in writing
fourth grading exam for kindergarten in writingfourth grading exam for kindergarten in writing
fourth grading exam for kindergarten in writing
 
Student login on Anyboli platform.helpin
Student login on Anyboli platform.helpinStudent login on Anyboli platform.helpin
Student login on Anyboli platform.helpin
 
The basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptxThe basics of sentences session 2pptx copy.pptx
The basics of sentences session 2pptx copy.pptx
 
Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..Sports & Fitness Value Added Course FY..
Sports & Fitness Value Added Course FY..
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and Mode
 
A Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformA Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy Reform
 
microwave assisted reaction. General introduction
microwave assisted reaction. General introductionmicrowave assisted reaction. General introduction
microwave assisted reaction. General introduction
 
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
 
General AI for Medical Educators April 2024
General AI for Medical Educators April 2024General AI for Medical Educators April 2024
General AI for Medical Educators April 2024
 
Arihant handbook biology for class 11 .pdf
Arihant handbook biology for class 11 .pdfArihant handbook biology for class 11 .pdf
Arihant handbook biology for class 11 .pdf
 

10 hypertension

  • 1. Hypertension Physiology, Pathophysiology and Clinical Managements Jun Tao
  • 2. Stroke and Ischemic Heart Disease (IHD) Mortality Rate in Each Decade of Age, Versus Usual Systolic BP at the Start of that Decade Mortality* Usual SBP (mmHg) 50–59 y 60–69 y 70–79 y 80–89 y Stroke Age at risk 256 128 64 32 16 8 4 2 1 0 120 140 160 180 IHD Usual SBP (mmHg ) 50–59 y 60–69 y 70–79 y 80–89 y Age at risk 40–49 y 256 128 64 32 16 8 4 2 1 0 120 140 160 180 *Floating absolute risk and 95% CI Reproduced from The Lancet, 360, Lewington et al. pp. 1903–13 Copyright © 2002, with permission from Elsevier
  • 3.
  • 4.
  • 5.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.  
  • 20.
  • 21.
  • 22.
  • 23.
  • 24.
  • 25.
  • 26. Hpertrophy of left ventricle
  • 27.  
  • 28.
  • 29.
  • 30.  
  • 31.  
  • 32.
  • 33.
  • 35. Malignant hypertension: Fibrinoid necrosis of damaged arteriole of kidney
  • 36.
  • 37.  
  • 38.
  • 39.
  • 40.
  • 41.
  • 42.
  • 43.
  • 44.
  • 45.
  • 46.
  • 47.
  • 48.
  • 49.
  • 50.  
  • 51.
  • 52. Cardiovascular risk category of hypertension   Blood pressure ( mmHg ) Grade 1(SBP 140 ~ 159 or DBP 90 ~ 99) Grade 2(SBP 160 ~ 179 or DBP 100 ~ 109) Grade 3(SBP ≥180 or DBP ≥110) No other risk factors Low-risk Medium-risk High-risk 1 ~ 2 risk factors Moderate-risk Medium-risk Very High-risk 3 or more risk factors , or diabetes , or target organ damage High-risk High-risk Very High-risk complications Very High-risk Very High-risk Very High-risk
  • 53.
  • 54.
  • 55.
  • 56.
  • 57.
  • 58.
  • 59. Algorithm for Treatment of Hypertension Not at Goal Blood Pressure (<140/90 mmHg) (<130/80 mmHg for those with diabetes or chronic kidney disease) Initial Drug Choices Lifestyle Modifications Drug(s) for the compelling indications Other antihypertensive drugs (diuretics, ACEI, ARB, BB, CCB) as needed. With Compelling Indications Stage 2 Hypertension (SBP > 160 or DBP > 100 mmHg) 2-drug combination for most (usually thiazide-type diuretic and ACEI, or ARB, or BB, or CCB) Stage 1 Hypertension (SBP 140–159 or DBP 90–99 mmHg) Thiazide-type diuretics for most. May consider ACEI, ARB, BB, CCB, or combination. Without Compelling Indications Not at Goal Blood Pressure Optimize dosages or add additional drugs until goal blood pressure is achieved. Consider consultation with hypertension specialist.
  • 60.
  • 61.
  • 62.
  • 63.
  • 64.
  • 65.
  • 66.
  • 67.  
  • 68.  
  • 69. Classification and Management of BP for adults *Treatment determined by highest BP category. † Initial combined therapy should be used cautiously in those at risk for orthostatic hypotension. ‡ Treat patients with chronic kidney disease or diabetes to BP goal of <130/80 mmHg. BP classification SBP* mmHg DBP* mmHg Lifestyle modification Initial drug therapy Without compelling indication With compelling indications Normal <120 and <80 Encourage Prehypertension 120–139 or 80–89 Yes No antihypertensive drug indicated. Drug(s) for compelling indications. ‡ Stage 1 Hypertension 140–159 or 90–99 Yes Thiazide-type diuretics for most. May consider ACEI, ARB, BB, CCB, or combination. Drug(s) for the compelling indications. ‡ Other antihypertensive drugs (diuretics, ACEI, ARB, BB, CCB) as needed. Stage 2 Hypertension > 160 or > 100 Yes Two-drug combination for most † (usually thiazide-type diuretic and ACEI or ARB or BB or CCB).
  • 70.  
  • 71.  
  • 72. Other medications for hypertensive patients Primary prevention ( 1 ) Aspirin: use 75mg daily if patient is aged  50 years with blood pressure controlled to <150/90 mm Hg and either; target organ damage, diabetes mellitus, or 10 year risk of cardiovascular disease of  20% (measured by using the new Joint British Societies’ cardiovascular disease risk chart) ( 2 ) Statin: use sufficient doses to reach targets if patient is aged up to at least 80 years, with a 10 year risk of cardiovascular disease of  20% (measured by using the new Joint British Societies’ cardiovascular disease risk chart) and with total cholesterol concentration  3.5mmol/l ( 3 ) Vitamins—no benefit shown, do not prescribe
  • 73.
  • 74. Targets for lipid lowering Ideal - TC<4.0mmol/l or LDL <2.0mmol/l or 25%  in TC or 30%  in LDL-C whichever is the greater ‘ Audit’ - TC <5.0mmol/l or LDL <3.0mmol/l or 25%  in TC or 30%  in LDL-C whichever is the greater Lipid targets
  • 75.
  • 76.
  • 77.
  • 78. ESH - ESC Guidelines, J Hypertens 2008 -BP < 140/90 mmHg in all hypertensive patients < 130/80 mmHg in hypertensive patients with diabetes or renal disease -Control of all cardiovascular risk factors Goals of treatment
  • 79.
  • 80.

Notas do Editor

  1. These data are taken from a meta-analysis of 61 prospective observational studies on deaths from vascular disease among subjects without vascular disease at baseline. The results demonstrated that the relationship of stroke mortality (left panel) and ischemic heart disease (IHD) mortality (right panel) to usual BP is strong and direct at all ages. As highlighted on the following slide, each difference of 20 mmHg in usual systolic BP is associated with a two-fold difference in the risk of stroke mortality and IHD mortality (between ages 40–69 years). The annual absolute difference in risk is greater in old age. Reference Lewington S, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903–13.
  2. Trials have shown that BP lowering can produce rapid reductions in cardiovascular disease risk. In fact, even a 2 mmHg decrease in systolic BP would result in approximately 7% lower mortality risk from ischemic heart disease and a 10% lower mortality risk from stroke. Reference Lewington S, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903–13.
  3. bhs guidelines 2004.boeh-ingel
  4. bhs guidelines 2004.boeh-ingel
  5. bhs guidelines 2004.boeh-ingel
  6. bhs guidelines 2004.boeh-ingel
  7. bhs guidelines 2004.boeh-ingel